HSP90AA1 and colorectal carcinoma: This trial has prompted interest in further studies (possibly a randomized phase II/III) to see if Hsp90 inhibitors, in combination with PD-1 blockade, could benefit a subset of MSS CRC or other checkpoint-refractory solid tumors.